Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function
Launched by DR. LOGES & CO. GMBH · Mar 18, 2015
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
25 patients were included in the trial. Intervention period was 4 weeks with 2 months wash out phase. The screening visit of all volunteers before study start included volunteer information, signature of informed consent, anamnesis, medical history, ECG and blood routine analysis.
Efficacy parameters were measured at visit 1, 2, 3, and 4. Endothelial function and postprandial endothelial Reaction was tested using EndoPAT (validated diagnosis tool). Blood pressure was measured by volunteers over a period of 7 days before each visit. As additional parameters homocysteine and ADMA (assymmetri...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • borderline blood pressure (systolic 130-149)
- • homocystein level \>10µmol/l
- Exclusion Criteria:
- • e.g.
- • BMI \<20kg/m2 and \>32kg/m2
- • use of antihypertensives, anticoagulants, and statins
- • cardiovascular diseases e.g. stroke, myocardial infarction
- • use of L-arginine and other dietary supplements
About Dr. Loges & Co. Gmbh
dr. loges & co. gmbh is a leading clinical trial sponsor specializing in the development and commercialization of innovative therapeutic solutions. With a strong commitment to advancing healthcare, the company focuses on conducting rigorous clinical research to evaluate the safety and efficacy of novel treatments. Leveraging a team of experienced professionals and a robust network of clinical partners, dr. loges & co. gmbh aims to deliver high-quality results that contribute to improved patient outcomes and drive advancements in medical science. Their dedication to ethical practices and regulatory compliance ensures that all trials are conducted with the utmost integrity and transparency.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Esslingen, , Germany
Patients applied
Trial Officials
Birgit Goyvaerts, Dr.
Study Chair
medical advisor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials